Alkermes plc (NASDAQ:ALKS) Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. cut its position in shares of Alkermes plc (NASDAQ:ALKS) by 27.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,402,819 shares of the company’s stock after selling 523,805 shares during the quarter. Goldman Sachs Group Inc. owned about 0.84% of Alkermes worth $38,914,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its position in shares of Alkermes by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,403,195 shares of the company’s stock worth $66,666,000 after buying an additional 90,219 shares during the period. S&CO Inc. boosted its position in shares of Alkermes by 13.2% in the fourth quarter. S&CO Inc. now owns 173,145 shares of the company’s stock worth $4,803,000 after buying an additional 20,145 shares during the period. Handelsbanken Fonder AB boosted its position in shares of Alkermes by 521.3% in the fourth quarter. Handelsbanken Fonder AB now owns 175,200 shares of the company’s stock worth $4,860,000 after buying an additional 147,000 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Alkermes by 81.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 377,489 shares of the company’s stock worth $10,472,000 after buying an additional 169,385 shares during the period. Finally, RTW Investments LP boosted its position in shares of Alkermes by 338.8% in the fourth quarter. RTW Investments LP now owns 3,901,523 shares of the company’s stock worth $108,228,000 after buying an additional 3,012,450 shares during the period. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Alkermes Trading Down 0.4 %

Shares of NASDAQ ALKS opened at $24.95 on Friday. The stock’s 50 day moving average price is $24.23 and its two-hundred day moving average price is $26.64. Alkermes plc has a 52-week low of $22.01 and a 52-week high of $33.71. The stock has a market capitalization of $4.22 billion, a P/E ratio of 9.86, a PEG ratio of 0.49 and a beta of 0.47. The company has a quick ratio of 2.77, a current ratio of 3.20 and a debt-to-equity ratio of 0.23.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $0.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.58 by ($0.15). The firm had revenue of $350.37 million for the quarter, compared to analyst estimates of $360.26 million. Alkermes had a net margin of 25.17% and a return on equity of 20.31%. The company’s quarterly revenue was up 21.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.10) EPS. On average, analysts anticipate that Alkermes plc will post 2.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ALKS. StockNews.com downgraded Alkermes from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. HC Wainwright reissued a “neutral” rating and issued a $35.00 price target on shares of Alkermes in a report on Tuesday, June 4th. Jefferies Financial Group increased their price target on Alkermes from $42.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, April 9th. TD Cowen began coverage on Alkermes in a report on Monday, June 17th. They issued a “buy” rating and a $34.00 price target for the company. Finally, Cantor Fitzgerald increased their price target on Alkermes from $43.00 to $48.00 and gave the company an “overweight” rating in a report on Thursday, May 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $36.50.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.